Q. For a patient of NSCLC having N2 (stage III) disease, which of the following is an accepted management option :
A. Concurrent chemoradiation followed by adjuvant chemotherapy
B. Concurrent chemoradiation followed by immune checkpoint inhibitor therapy
C. Both of the above
D. Neither I nor 2
Answer: Both of the above
